Fibrocell Science Inc
Fibrocell Science Inc is a private biotechnology company founded in 1995 in Exton, Pennsylvania that develops autologous cell and gene therapies for diseases of the skin and connective tissue.
- Company typePrivate
- Founded1995
- HeadquartersExton, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fibrocell Science Inc does
Fibrocell Science Inc is a private, for-profit biotechnology company founded in 1995 and headquartered in Exton, Pennsylvania. According to the firmographic description provided, the company develops autologous cell and gene therapies targeted at diseases of the skin and connective tissue. Its therapeutic approach is autologous, meaning treatments are derived from a patient's own cells, placing the company within the personalized regenerative medicine segment of the biotech industry.
The company's product offering, specific pipeline assets, clinical development stage, manufacturing approach, and underlying technical platform were not disclosed in the source material. As a private entity operating in a regulated biologics category, its economics would typically be driven by long-cycle R&D investment, clinical milestones, and potential partnerships or licensing with larger pharmaceutical companies; however, no funding history, capitalization, partnership agreements, or commercialization signals were available. The source data also contained substantial unrelated content about an unrelated gambling website and a t-shirt marketplace, which carries no information about the company.
No information was provided on headcount, revenue, ownership structure, operating status, customer segments, distribution channels, or recent strategic actions. Any analytical conclusions beyond the company's stated therapeutic focus, founding year, and location should be treated as unsupported by the available data.
Fibrocell Science Inc firmographics
Firmographics- Name
- Fibrocell Science Inc
- Website
- https://www.fibrocell.com
- Company type
- Private
- Founded year
- 1995
- Short description
- Fibrocell Science Inc is a private biotechnology company founded in 1995 in Exton, Pennsylvania that develops autologous cell and gene therapies for diseases of the skin and connective tissue.
- Ownership category
- akta.pro rank
Fibrocell Science Inc industry classification
Industry- Product category
- Cell and Gene Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Fibrocell Science Inc is headquartered
LocationHeadquarters
- HQ city
- Exton
- HQ country
- United States
- HQ region
- North America
Markets served
Fibrocell Science Inc business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Fibrocell Science Inc product offering
Product offeringCore offering
Fibrocell Science develops autologous cell and gene therapies intended for the treatment of diseases of the skin and connective tissue. The company's product work is centered on patient-derived (autologous) cellular and gene-based therapeutic candidates aimed at dermatological and connective-tissue indications.
Differentiator
Problem solved
Functional benefit
Companies that use Fibrocell Science Inc
Customer profileIdeal customer profiles1 record
Fibrocell Science Inc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Fibrocell Science Inc competitors and assessment
Company assessmentDirect peers
- Castle Creek Biosciences: Develops autologous cell and gene therapies for recessive dystrophic epidermolysis bullosa and other skin/connective tissue diseases — directly overlapping Fibrocell's therapeutic focus and autologous modality.
- Krystal Biotech: Commercial-stage gene therapy company focused on skin diseases (e.g., Vyjuvek for dystrophic EB); directly comparable therapeutic area and connective tissue modality to Fibrocell.
- Abeona Therapeutics: Clinical-stage cell and gene therapy developer with EB and skin-focused programs; shares Fibrocell's autologous gene-therapy approach and rare dermatology focus.
- Vericel: Commercial autologous cell therapy company (MACI for cartilage repair, Epicel for burns); shares the autologous manufacturing platform and skin/connective tissue adjacency.
Broad incumbents
- Organogenesis: Established regenerative medicine company in wound care and skin/connective tissue repair; broader portfolio than Fibrocell but operates in overlapping tissue regeneration categories.
Emerging players
- AIVITA Biomedical: Clinical-stage cell therapy developer with autologous dendritic cell and skin/wound programs; comparable autologous modality and emerging commercial stage.
- StemBioCell: Early-stage autologous cell therapy developer focused on skin and connective tissue indications; overlaps with Fibrocell's niche and modality.
- RHEACELL: Clinical-stage developer of cell-based therapies for wound healing and skin regeneration; comparable autologous cell therapy modality and dermatology focus.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights3 records
Customer concentration
Fibrocell Science Inc social profiles
Digital presenceFibrocell Science Inc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fibrocell Science Inc leadership team
Management profileNumber of profiles
Fibrocell Science Inc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fibrocell Science Inc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fibrocell Science Inc
What does Fibrocell Science Inc do?
Fibrocell Science develops autologous cell and gene therapies intended for the treatment of diseases of the skin and connective tissue. The company's product work is centered on patient-derived (autologous) cellular and gene-based therapeutic candidates aimed at dermatological and connective-tissue indications.
When was Fibrocell Science Inc founded?
Fibrocell Science Inc was founded in 1995.
Where is Fibrocell Science Inc based?
Fibrocell Science Inc is headquartered in Exton, United States, in the North America region.
Who are Fibrocell Science Inc's main competitors?
Direct peers on record are Castle Creek Biosciences, Krystal Biotech, Abeona Therapeutics and Vericel. Organogenesis is listed as a broad incumbent. Emerging players are AIVITA Biomedical, StemBioCell and RHEACELL.
Does Fibrocell Science Inc have an API?
No public API is recorded for Fibrocell Science Inc.
What industry is Fibrocell Science Inc in?
Fibrocell Science Inc's product category is Cell and Gene Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.